Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: Amulticenter retrospective study

Talia Golan, Maria Raitses-Gurevich, Robin K. Kelley, Andrea G. Bocobo, Ayelet Borgida, Rachna T. Shroff, Spring Holter, Steven Gallinger, Daniel Ahn, Dan Aderka, Jain Apurva, Tanios Bekaii-Saab, Eitan Friedman, Milind Javle

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. Biliary tract malignancies, in particular cholangiocarcinomas (CCA), are rare tumors that carry a poor prognosis. BRCA2 mutation carriers have an increased risk of developing CCA with a reported relative risk of ~5 according to the Breast Cancer Linkage Consortium. In addition to this risk, there are potential therapeutic implications in those harboring somatic and/or germline (GL) BRCA mutations. Therefore, it is important to define the clinical characteristics of GL/somatic BRCA1/2 variants in CCA patients. Materials and Methods.We performed a multicenter retrospective analysis of CCA patients diagnosed between January 2000 and December 2013 with GL or somatic variants in BRCA1/2 genes detected by GL mutations testing and/or by tumor next generation sequencing. Cases were identified from clinical databases at participating institutions. Data including demographics, clinical history, surgical procedures, and systemic chemotherapy or radiation were extracted from patients’ records. Results. Overall, 18 cases were identified: 5 carriers of GL BRCA1/2 mutations (4 BRCA2; 1 BRCA1) and 13 harboring somatic variations (7 BRCA1; 6 BRCA2). Mean age at diagnosis was 60, SD±10 years (range 36–75 years), with male and female prevalence rates of 61.2% and 38.8%, respectively. Stage at diagnosis was I (n54), II (n53), III (n53), and IV (n58). Six patients had extrahepatic CCA and the rest intrahepatic CCA. Thirteen patients received platinumbased therapy and four were treated with poly ADP ribose polymerase inhibitors, of whom one experienced sustained disease response with a progression-free survival of 42.6 months. Median overall survival from diagnosis for patients with stage I/II in this study was 40.3 months (95% confidence interval [CI], 6.73–108.15) and with stages III/IV was 25 months (95% CI, 15.23–40.57). Conclusion. BRCA-associated CCA is uncommon. This multicenter retrospective study provides a thorough clinical analysis of a BRCA-associated CCA cohort, which can serve as a benchmark for future development and design of expanded analyses and clinical trials.

Original languageEnglish (US)
Pages (from-to)804-810
Number of pages7
JournalOncologist
Volume22
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Cholangiocarcinoma
Retrospective Studies
Survival
Germ-Line Mutation
Confidence Intervals
BRCA1 Gene
Benchmarking
Neoplasms
Mutation
Biliary Tract
Multicenter Studies
Disease-Free Survival
Demography
Clinical Trials
Databases
Radiation
Breast Neoplasms
Drug Therapy
Therapeutics

Keywords

  • BRCA-associated
  • Cholangiocarcinoma
  • Germline
  • PARPi
  • Somatic

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Golan, T., Raitses-Gurevich, M., Kelley, R. K., Bocobo, A. G., Borgida, A., Shroff, R. T., ... Javle, M. (2017). Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: Amulticenter retrospective study. Oncologist, 22(7), 804-810. https://doi.org/10.1634/theoncologist.2016-0415

Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma : Amulticenter retrospective study. / Golan, Talia; Raitses-Gurevich, Maria; Kelley, Robin K.; Bocobo, Andrea G.; Borgida, Ayelet; Shroff, Rachna T.; Holter, Spring; Gallinger, Steven; Ahn, Daniel; Aderka, Dan; Apurva, Jain; Bekaii-Saab, Tanios; Friedman, Eitan; Javle, Milind.

In: Oncologist, Vol. 22, No. 7, 01.07.2017, p. 804-810.

Research output: Contribution to journalArticle

Golan, T, Raitses-Gurevich, M, Kelley, RK, Bocobo, AG, Borgida, A, Shroff, RT, Holter, S, Gallinger, S, Ahn, D, Aderka, D, Apurva, J, Bekaii-Saab, T, Friedman, E & Javle, M 2017, 'Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: Amulticenter retrospective study', Oncologist, vol. 22, no. 7, pp. 804-810. https://doi.org/10.1634/theoncologist.2016-0415
Golan, Talia ; Raitses-Gurevich, Maria ; Kelley, Robin K. ; Bocobo, Andrea G. ; Borgida, Ayelet ; Shroff, Rachna T. ; Holter, Spring ; Gallinger, Steven ; Ahn, Daniel ; Aderka, Dan ; Apurva, Jain ; Bekaii-Saab, Tanios ; Friedman, Eitan ; Javle, Milind. / Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma : Amulticenter retrospective study. In: Oncologist. 2017 ; Vol. 22, No. 7. pp. 804-810.
@article{fdf161bb5cbf40249980c6dfa1dbcbb9,
title = "Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: Amulticenter retrospective study",
abstract = "Background. Biliary tract malignancies, in particular cholangiocarcinomas (CCA), are rare tumors that carry a poor prognosis. BRCA2 mutation carriers have an increased risk of developing CCA with a reported relative risk of ~5 according to the Breast Cancer Linkage Consortium. In addition to this risk, there are potential therapeutic implications in those harboring somatic and/or germline (GL) BRCA mutations. Therefore, it is important to define the clinical characteristics of GL/somatic BRCA1/2 variants in CCA patients. Materials and Methods.We performed a multicenter retrospective analysis of CCA patients diagnosed between January 2000 and December 2013 with GL or somatic variants in BRCA1/2 genes detected by GL mutations testing and/or by tumor next generation sequencing. Cases were identified from clinical databases at participating institutions. Data including demographics, clinical history, surgical procedures, and systemic chemotherapy or radiation were extracted from patients’ records. Results. Overall, 18 cases were identified: 5 carriers of GL BRCA1/2 mutations (4 BRCA2; 1 BRCA1) and 13 harboring somatic variations (7 BRCA1; 6 BRCA2). Mean age at diagnosis was 60, SD±10 years (range 36–75 years), with male and female prevalence rates of 61.2{\%} and 38.8{\%}, respectively. Stage at diagnosis was I (n54), II (n53), III (n53), and IV (n58). Six patients had extrahepatic CCA and the rest intrahepatic CCA. Thirteen patients received platinumbased therapy and four were treated with poly ADP ribose polymerase inhibitors, of whom one experienced sustained disease response with a progression-free survival of 42.6 months. Median overall survival from diagnosis for patients with stage I/II in this study was 40.3 months (95{\%} confidence interval [CI], 6.73–108.15) and with stages III/IV was 25 months (95{\%} CI, 15.23–40.57). Conclusion. BRCA-associated CCA is uncommon. This multicenter retrospective study provides a thorough clinical analysis of a BRCA-associated CCA cohort, which can serve as a benchmark for future development and design of expanded analyses and clinical trials.",
keywords = "BRCA-associated, Cholangiocarcinoma, Germline, PARPi, Somatic",
author = "Talia Golan and Maria Raitses-Gurevich and Kelley, {Robin K.} and Bocobo, {Andrea G.} and Ayelet Borgida and Shroff, {Rachna T.} and Spring Holter and Steven Gallinger and Daniel Ahn and Dan Aderka and Jain Apurva and Tanios Bekaii-Saab and Eitan Friedman and Milind Javle",
year = "2017",
month = "7",
day = "1",
doi = "10.1634/theoncologist.2016-0415",
language = "English (US)",
volume = "22",
pages = "804--810",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma

T2 - Amulticenter retrospective study

AU - Golan, Talia

AU - Raitses-Gurevich, Maria

AU - Kelley, Robin K.

AU - Bocobo, Andrea G.

AU - Borgida, Ayelet

AU - Shroff, Rachna T.

AU - Holter, Spring

AU - Gallinger, Steven

AU - Ahn, Daniel

AU - Aderka, Dan

AU - Apurva, Jain

AU - Bekaii-Saab, Tanios

AU - Friedman, Eitan

AU - Javle, Milind

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background. Biliary tract malignancies, in particular cholangiocarcinomas (CCA), are rare tumors that carry a poor prognosis. BRCA2 mutation carriers have an increased risk of developing CCA with a reported relative risk of ~5 according to the Breast Cancer Linkage Consortium. In addition to this risk, there are potential therapeutic implications in those harboring somatic and/or germline (GL) BRCA mutations. Therefore, it is important to define the clinical characteristics of GL/somatic BRCA1/2 variants in CCA patients. Materials and Methods.We performed a multicenter retrospective analysis of CCA patients diagnosed between January 2000 and December 2013 with GL or somatic variants in BRCA1/2 genes detected by GL mutations testing and/or by tumor next generation sequencing. Cases were identified from clinical databases at participating institutions. Data including demographics, clinical history, surgical procedures, and systemic chemotherapy or radiation were extracted from patients’ records. Results. Overall, 18 cases were identified: 5 carriers of GL BRCA1/2 mutations (4 BRCA2; 1 BRCA1) and 13 harboring somatic variations (7 BRCA1; 6 BRCA2). Mean age at diagnosis was 60, SD±10 years (range 36–75 years), with male and female prevalence rates of 61.2% and 38.8%, respectively. Stage at diagnosis was I (n54), II (n53), III (n53), and IV (n58). Six patients had extrahepatic CCA and the rest intrahepatic CCA. Thirteen patients received platinumbased therapy and four were treated with poly ADP ribose polymerase inhibitors, of whom one experienced sustained disease response with a progression-free survival of 42.6 months. Median overall survival from diagnosis for patients with stage I/II in this study was 40.3 months (95% confidence interval [CI], 6.73–108.15) and with stages III/IV was 25 months (95% CI, 15.23–40.57). Conclusion. BRCA-associated CCA is uncommon. This multicenter retrospective study provides a thorough clinical analysis of a BRCA-associated CCA cohort, which can serve as a benchmark for future development and design of expanded analyses and clinical trials.

AB - Background. Biliary tract malignancies, in particular cholangiocarcinomas (CCA), are rare tumors that carry a poor prognosis. BRCA2 mutation carriers have an increased risk of developing CCA with a reported relative risk of ~5 according to the Breast Cancer Linkage Consortium. In addition to this risk, there are potential therapeutic implications in those harboring somatic and/or germline (GL) BRCA mutations. Therefore, it is important to define the clinical characteristics of GL/somatic BRCA1/2 variants in CCA patients. Materials and Methods.We performed a multicenter retrospective analysis of CCA patients diagnosed between January 2000 and December 2013 with GL or somatic variants in BRCA1/2 genes detected by GL mutations testing and/or by tumor next generation sequencing. Cases were identified from clinical databases at participating institutions. Data including demographics, clinical history, surgical procedures, and systemic chemotherapy or radiation were extracted from patients’ records. Results. Overall, 18 cases were identified: 5 carriers of GL BRCA1/2 mutations (4 BRCA2; 1 BRCA1) and 13 harboring somatic variations (7 BRCA1; 6 BRCA2). Mean age at diagnosis was 60, SD±10 years (range 36–75 years), with male and female prevalence rates of 61.2% and 38.8%, respectively. Stage at diagnosis was I (n54), II (n53), III (n53), and IV (n58). Six patients had extrahepatic CCA and the rest intrahepatic CCA. Thirteen patients received platinumbased therapy and four were treated with poly ADP ribose polymerase inhibitors, of whom one experienced sustained disease response with a progression-free survival of 42.6 months. Median overall survival from diagnosis for patients with stage I/II in this study was 40.3 months (95% confidence interval [CI], 6.73–108.15) and with stages III/IV was 25 months (95% CI, 15.23–40.57). Conclusion. BRCA-associated CCA is uncommon. This multicenter retrospective study provides a thorough clinical analysis of a BRCA-associated CCA cohort, which can serve as a benchmark for future development and design of expanded analyses and clinical trials.

KW - BRCA-associated

KW - Cholangiocarcinoma

KW - Germline

KW - PARPi

KW - Somatic

UR - http://www.scopus.com/inward/record.url?scp=85024096864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024096864&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2016-0415

DO - 10.1634/theoncologist.2016-0415

M3 - Article

C2 - 28487467

AN - SCOPUS:85024096864

VL - 22

SP - 804

EP - 810

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -